Intensification of remission induction therapy for acute nonlymphocytic leukemia (ANLL). I. Response and toxicity in four different regimens.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to D Urbanitz.
Explore the source record for details and available documents.
31 adult patients (study A) with acute myelocytic leukaemia were treated for remission induction with cytosine arabinoside (ARA-C, 100 mg/m2/day) by a 7 (5) day continuous infusion. 3 (2) doses of daunorubicin (DNR, 45 mg/m2 i.v.) were added at daily intervals. For maintenance 5 day ARA-C was given monthly in sequential combination with DNR, thioguanine (TG), or ifosfamide (IFOS). 16 (52%) patients achieved complete remission (C.R.) after 1.8 (1-3) courses and 6.7 (3-10) weeks from treatment start. The median survival for responders and non-responders was 11.5 months, early death rate within 6 weeks was 3 (10%). Median remission duration was 13.5 months. Among 11 patients surving for 7-22 months 7 patients are in first remission for 5.5-20.5 months. DNR, IFOS and TG were given before the 3rd day of ARA-C infusion. In a previous group of 34 leukaemic patients and in 44 therapy courses DNA histograms of bone marrow cells using pulse cytophotometry showed marked accumulation in S-phase for 75% of courses. Also (G2 + M)-cells in the DNA distribution and thymidine pulse labelling indices were markedly increased in most cases, whereas thymidine uptake by scintillation counter was diminished and mitotic indices had not changed significantly. In now 15 patients (study B) the induction regimen was intensified by adding vincristine (VCR, 2 mg i.v.) and 3 doses of IFOS (600 mg/m2 i.v.). Preliminary results are 50% C.R. after 1,7 (1-2) courses and 6.8 (5-10) weeks from initiation of therapy. 2 patients died in the first 6 weeks.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A case is reported of a 34 year old woman, who was hospitalized because of cardiopulmonary shock of sudden unsuspected onset. X-ray examination revealed diffuse interstitial pulmonary infiltration. Intra-aortal counter-pulsation did improve the condition only for short time. On autopsy an adenocarcinoma of the stomach was found, as well as diffuse carcinomatous infiltration of pulmonary lymph and arterial vessels. Thus lymphangiosis carcinomatosa has to be taken into consideration in discussing the differential diagnosis of diffuse interstitial pulmonary infiltration in young patients. The presence of microangiopathic hemolytic anemia may help to establish the diagnosis.
The monocytes of 7 patients with advanced Hdgkin's disease (stages III and IV) and of two patients with generalized lymphosarcoma exhibited a highly significant impairment of the phagocytosis of IgG-coated red cells, regardless of receiving therapy or not. In contrast three patients with M. Hodgkin, stage II B, and one with lymphosarcoma in complete remission showed a rather elevated monocyte phagocytic acitivity. The nitroblue tetrazolium reduction by monocytes in the mean was significantly enhanced in all patients investigated, compared with normal persons, although only in one patient a bacterial infection was apparent at the time of the test. The possible implication of the findings in the well known immunodeficiency present in M. Hodgkin and lymphosarcoma is discussed.
Monocyte function studies in vitro have been performed in 21 patients with terminal, dialysis-treated uremia and, in parallel, in 21 healthy normal subjects. In uremia the attachment, spreading activity, and reduction of nitroblue tetrazolium were shown to be significantly enhanced, indicating a metabolic activation of the monocytes. The phagocytosis of IgG-coated red cells, however, was significantly impaired. A modification of the monocyte IgG-receptor in uremic conditions is supposed; its relevance for the immunosuppression in uremic states is discussed.
Depending upon the NBT charge 50 to 80% of isolated non stimulated human monocytes reduce NBT ro morphologically demonstrable Formazan. Similar to neutrophils two different patterns of reaction are exhibited: discrete load with finely distributed Formazan granula surrounding the nucleus; massive reaction with large distributed Formazan granula surrounding the nucleus; massive reaction with large Formazan deposits throughout the cytoplasma. In a low percentage morphologically desintegrated, massive loaden cells appear. After an additional incubation in medium without NBT the number of these necrotic cells increases. The phagocytosis of IgG-coated red cells is impaired after incubation of the monocytes in NBT. In the presence of an alkylating agent not only the NBT-reaction is inhibited; the number of necrotic cells is also diminished. Apparently the Formazan is cytotoxic. The significance of these results in particular in cases of enhanced NBT reduction is discussed. Compared with the findings of other authors concerning the neutrophils the monocytes possess a markedly stronger NBT reducing activity. Considering the lower bactericidal capacity of the monocytes NBT reduction does not in every case parallel bactericidal activity.
Resistance to bacterial infection, particularly septicemia and pneumonia, is decreased in patients with uremia. Tests of monocyte function in 21 patients with chronic uremia and in 21 normal healthy subjects showed an increase in attachment rate, spreading activity and Nirtoblue-tetrazolium reduction in the uremic subjects. In contrast, phagocytosis of IgG-coated red cells was impaired.
Explore the source record for details and available documents.